Abstract
Edoxaban is a factor Xa inhibitor that is approved for prevention of stroke in individuals with atrial fibrillation and treatment of venous thromboembolic disease at once daily 60 mg dose for individuals with normal renal function. A decrease of dose to 30 mg is recommended for those with moderate renal insufficiency, weight ≤ 60 kg or simultaneous administration of strong P-glycoprotein inhibitors. At this time, it is not recommended for use in persons with either end stage renal disease or with GFR exceeding 95 mL/min. Shorter half-life averaging 8-10 hours may translate into a safer profile. With a fast onset of action of ~1.5 hours and relatively high bioavailability, edoxaban is an alternative for patients who may not be good candidates for warfarin therapy due to multiple limitations that vitamin K anticoagulation entails. No clear benefits of edoxaban have been reported to date compared to the other available factor Xa inhibitors.
Keywords: Edoxaban, oral anticoagulation, pharmacodynamics, pharmacokinetics.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy
Volume: 13 Issue: 2
Author(s): Maryna Popp Switzer, Priyanka Wani, Sucheta Gosavi and Debabrata Mukherjee
Affiliation:
Keywords: Edoxaban, oral anticoagulation, pharmacodynamics, pharmacokinetics.
Abstract: Edoxaban is a factor Xa inhibitor that is approved for prevention of stroke in individuals with atrial fibrillation and treatment of venous thromboembolic disease at once daily 60 mg dose for individuals with normal renal function. A decrease of dose to 30 mg is recommended for those with moderate renal insufficiency, weight ≤ 60 kg or simultaneous administration of strong P-glycoprotein inhibitors. At this time, it is not recommended for use in persons with either end stage renal disease or with GFR exceeding 95 mL/min. Shorter half-life averaging 8-10 hours may translate into a safer profile. With a fast onset of action of ~1.5 hours and relatively high bioavailability, edoxaban is an alternative for patients who may not be good candidates for warfarin therapy due to multiple limitations that vitamin K anticoagulation entails. No clear benefits of edoxaban have been reported to date compared to the other available factor Xa inhibitors.
Export Options
About this article
Cite this article as:
Switzer Popp Maryna, Wani Priyanka, Gosavi Sucheta and Mukherjee Debabrata, Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (2) . https://dx.doi.org/10.2174/187152571302151217130638
DOI https://dx.doi.org/10.2174/187152571302151217130638 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Research Strategies for Pain in Lumbar Radiculopathy Focusing on Acid-Sensing Ion Channels and Their Toxins
Current Topics in Medicinal Chemistry Designing Phage Therapeutics
Current Pharmaceutical Biotechnology Patented Novelties in Immunoisolation for the Treatment of Endocrine Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update
Current Pharmaceutical Design Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Hypertension in Pregnancy: A Review of Current Guidelines
Current Women`s Health Reviews Shear Stress-sensitive Carriers for Localized Drug Delivery
Current Pharmaceutical Design Exercise Limitation in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Emerging Anticoagulants
Current Medicinal Chemistry Clozapine Safety, 40 Years Later
Current Drug Safety Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry Autophagy in Diabetic Retinopathy
Current Neuropharmacology Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews Thiopurines in Inflammatory Bowel Disease - The Role of Pharmacogenetics and Therapeutic Drug Monitoring
Current Pharmacogenomics Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology New Insights into the Surgical Management of Tetralogy of Fallot: Physiological Fundamentals and Clinical Relevance
Current Pediatric Reviews Hemothorax
Current Respiratory Medicine Reviews